BrickBio Creates Novel Class of Bispecific Antibody Drug Conjugate and Receives Green Light on Next Phase of Therapeutic Deal with Large Pharma Partner
BOSTON, Jan. 19, 2021 /PRNewswire/ — The leader in site specific bioconjugation and DAR (drug to antibody ratio) optimization in antibody drug conjugates (ADCs) and protein therapeutics, has created a novel class of bispecific antibodies that have the ability to be labeled and conjugated…
Comments Off on BrickBio Creates Novel Class of Bispecific Antibody Drug Conjugate and Receives Green Light on Next Phase of Therapeutic Deal with Large Pharma Partner